NO983372L - Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter - Google Patents
Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytterInfo
- Publication number
- NO983372L NO983372L NO983372A NO983372A NO983372L NO 983372 L NO983372 L NO 983372L NO 983372 A NO983372 A NO 983372A NO 983372 A NO983372 A NO 983372A NO 983372 L NO983372 L NO 983372L
- Authority
- NO
- Norway
- Prior art keywords
- ribavirin
- activated
- lymphocytes
- modulation
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/590,449 US5767097A (en) | 1996-01-23 | 1996-01-23 | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
US3609497P | 1997-01-17 | 1997-01-17 | |
PCT/US1997/000600 WO1997026883A1 (en) | 1996-01-23 | 1997-01-21 | Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes |
Publications (2)
Publication Number | Publication Date |
---|---|
NO983372D0 NO983372D0 (no) | 1998-07-22 |
NO983372L true NO983372L (no) | 1998-09-21 |
Family
ID=26712784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO983372A NO983372L (no) | 1996-01-23 | 1998-07-22 | Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0879056B1 (xx) |
KR (1) | KR100298158B1 (xx) |
CN (1) | CN1190198C (xx) |
AT (1) | ATE216886T1 (xx) |
BR (1) | BR9707154A (xx) |
CA (1) | CA2246162C (xx) |
CZ (1) | CZ293584B6 (xx) |
DE (1) | DE69712316T2 (xx) |
DK (1) | DK0879056T3 (xx) |
ES (1) | ES2172764T3 (xx) |
HU (1) | HU220105B (xx) |
IL (1) | IL125088A0 (xx) |
NO (1) | NO983372L (xx) |
NZ (1) | NZ330784A (xx) |
PL (1) | PL187439B1 (xx) |
PT (1) | PT879056E (xx) |
RU (1) | RU2186569C2 (xx) |
SI (1) | SI9720013A (xx) |
SK (1) | SK283342B6 (xx) |
UA (1) | UA46815C2 (xx) |
WO (1) | WO1997026883A1 (xx) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1302474A1 (en) * | 1996-10-16 | 2003-04-16 | Ribapharm, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US6039969A (en) | 1996-10-25 | 2000-03-21 | 3M Innovative Properties Company | Immune response modifier compounds for treatment of TH2 mediated and related diseases |
BR9917090A (pt) * | 1999-01-29 | 2001-10-16 | Icn Pharmaceuticals | Modulação de resposta imune por ribavirina |
US6455508B1 (en) * | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
RU2286172C2 (ru) | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
KR100801123B1 (ko) | 2000-08-17 | 2008-02-05 | 트리펩 아베 | 리바비린 함유 백신 및 이것의 사용 방법 |
ES2335979T3 (es) | 2001-09-14 | 2010-04-07 | Cytos Biotechnology Ag | Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso. |
RU2005133093A (ru) * | 2003-03-28 | 2006-07-27 | Фармассет, Инк. (Us) | Соединения для лечения флавивирусных инфекций |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
AU2006325225B2 (en) | 2005-12-14 | 2013-07-04 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
EP2051728A4 (en) * | 2006-03-09 | 2010-03-31 | Om Pharma | IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF ILLNESSES DUE TO OVERPRODUCTION OF INFLAMMATORY CYTOKINS |
KR101552227B1 (ko) | 2006-06-12 | 2015-09-10 | 사이토스 바이오테크놀로지 아게 | 올리고뉴클레오티드를 rna 박테리오파지의 바이러스-유사 입자로 패키징하는 방법 |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
UY34536A (es) | 2011-12-22 | 2013-07-31 | Alios Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CA2871547C (en) | 2012-05-25 | 2021-05-25 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
KR102327888B1 (ko) | 2012-12-21 | 2021-11-17 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
US9862743B2 (en) | 2013-10-11 | 2018-01-09 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69232706T2 (de) * | 1991-05-01 | 2002-11-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
-
1997
- 1997-01-21 KR KR1019980705645A patent/KR100298158B1/ko not_active IP Right Cessation
- 1997-01-21 CN CNB971917760A patent/CN1190198C/zh not_active Expired - Fee Related
- 1997-01-21 IL IL12508897A patent/IL125088A0/xx unknown
- 1997-01-21 UA UA98073815A patent/UA46815C2/uk unknown
- 1997-01-21 DK DK97904765T patent/DK0879056T3/da active
- 1997-01-21 AT AT97904765T patent/ATE216886T1/de not_active IP Right Cessation
- 1997-01-21 ES ES97904765T patent/ES2172764T3/es not_active Expired - Lifetime
- 1997-01-21 CA CA002246162A patent/CA2246162C/en not_active Expired - Lifetime
- 1997-01-21 RU RU98115594/14A patent/RU2186569C2/ru active
- 1997-01-21 EP EP97904765A patent/EP0879056B1/en not_active Revoked
- 1997-01-21 PL PL97328003A patent/PL187439B1/pl not_active IP Right Cessation
- 1997-01-21 PT PT97904765T patent/PT879056E/pt unknown
- 1997-01-21 CZ CZ19982329A patent/CZ293584B6/cs not_active IP Right Cessation
- 1997-01-21 NZ NZ330784A patent/NZ330784A/xx unknown
- 1997-01-21 DE DE69712316T patent/DE69712316T2/de not_active Revoked
- 1997-01-21 SI SI9720013A patent/SI9720013A/sl not_active IP Right Cessation
- 1997-01-21 SK SK1004-98A patent/SK283342B6/sk not_active IP Right Cessation
- 1997-01-21 WO PCT/US1997/000600 patent/WO1997026883A1/en active IP Right Grant
- 1997-01-21 BR BR9707154A patent/BR9707154A/pt not_active Application Discontinuation
- 1997-01-21 HU HU9900681A patent/HU220105B/hu not_active IP Right Cessation
-
1998
- 1998-07-22 NO NO983372A patent/NO983372L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK0879056T3 (da) | 2002-08-19 |
UA46815C2 (uk) | 2002-06-17 |
NO983372D0 (no) | 1998-07-22 |
WO1997026883A1 (en) | 1997-07-31 |
HUP9900681A2 (hu) | 1999-07-28 |
EP0879056B1 (en) | 2002-05-02 |
CZ293584B6 (cs) | 2004-06-16 |
ATE216886T1 (de) | 2002-05-15 |
ES2172764T3 (es) | 2002-10-01 |
CA2246162C (en) | 2000-04-04 |
SI9720013A (sl) | 1999-06-30 |
EP0879056A1 (en) | 1998-11-25 |
BR9707154A (pt) | 1999-05-25 |
PL328003A1 (en) | 1999-01-04 |
SK283342B6 (sk) | 2003-06-03 |
CA2246162A1 (en) | 1997-07-31 |
HUP9900681A3 (en) | 1999-12-28 |
CN1209747A (zh) | 1999-03-03 |
PL187439B1 (pl) | 2004-07-30 |
PT879056E (pt) | 2002-10-31 |
KR100298158B1 (ko) | 2001-09-06 |
DE69712316D1 (en) | 2002-06-06 |
EP0879056A4 (en) | 1999-01-13 |
CZ232998A3 (cs) | 1999-04-14 |
AU700642B2 (en) | 1999-01-14 |
KR19990081930A (ko) | 1999-11-15 |
NZ330784A (en) | 1999-02-25 |
DE69712316T2 (de) | 2003-01-02 |
CN1190198C (zh) | 2005-02-23 |
HU220105B (hu) | 2001-10-28 |
SK100498A3 (en) | 2001-03-12 |
IL125088A0 (en) | 1999-01-26 |
AU1747897A (en) | 1997-08-20 |
RU2186569C2 (ru) | 2002-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO983372D0 (no) | Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter | |
PT79182B (de) | Mittel zur transdermalen applikation von arzneimittelwirkstoffen | |
ATE113650T1 (de) | Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen. | |
DE3677897D1 (de) | Menschliche komplementfaktoren und ihre therapeutische verwendung. | |
DE59007178D1 (de) | Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate. | |
EP0219076A3 (en) | Sustained release composition | |
ES2168457T3 (es) | Composiciones farmaceuticas que comprenden una superoxido dismutasa. | |
DE68908117D1 (de) | N-acetylglukosamin als zytoprotektives mittel. | |
ES2098316T3 (es) | Procedimiento de purificacion de carrageninas comerciales. | |
EP1240899A3 (en) | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections | |
IT8548055A1 (it) | Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale | |
DE3686472D1 (de) | Cardiotonische phenyloxazolone. | |
ES8704903A1 (es) | Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido. | |
DK369886D0 (da) | Hidtil ukendte acylphosphotriamider og pharmaceutisk komposition indeholdende samme til aendring af lipidindholdet i blodplasma hospattedyr | |
MA21471A1 (fr) | Composition de tourrage et son utilisation dans le tourrage et le post-tourrage des peaux animales . | |
ATE87207T1 (de) | Azapropazon zur praevention von post-ischaemischem gewebeschaden. | |
EP1174141A3 (en) | Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes | |
SU1473139A1 (ru) | Средство, повышающее общую устойчивость организма | |
BG101696A (en) | Solid dosed out overmectine-aontaining medicamentous forms | |
ATE54941T1 (de) | Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |